Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

AR-V7-expressing metastatic prostate cancer is an aggressive phenotype with poor progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests that AR-V7-positive tumors may be enriched for DNA-repair defects, perhaps rendering them more sensitive to immune-checkpoint bloc...

Descripción completa

Detalles Bibliográficos
Autores principales: Boudadi, Karim, Suzman, Daniel L., Anagnostou, Valsamo, Fu, Wei, Luber, Brandon, Wang, Hao, Niknafs, Noushin, White, James R., Silberstein, John L., Sullivan, Rana, Dowling, Donna, Harb, Rana, Nirschl, Thomas R., Veeneman, Brendan A., Tomlins, Scott A., Wang, Yipeng, Jendrisak, Adam, Graf, Ryon P., Dittamore, Ryan, Carducci, Michael A., Eisenberger, Mario A., Haffner, Michael C., Meeker, Alan K., Eshleman, James R., Luo, Jun, Velculescu, Victor E., Drake, Charles G., Antonarakis, Emmanuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033362/
https://www.ncbi.nlm.nih.gov/pubmed/29983880
http://dx.doi.org/10.18632/oncotarget.25564

Ejemplares similares

Ejemplares similares